---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008196"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:33:10.303861+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma board changes: Kenyon retires, Brandt appointed

## Summary
- Dr. Julian Kenyon retired from Board on Feb 20, 2026; remains as medical advisor.
- Dr. Ralf Brandt appointed to Board same day; 30+ yrs pharma/oncology experience.
- Brandt to receive $45,000 annual compensation under Director Agreement.
- Brandt has served as CEO of vivoPharm and held exec roles at Novartis and Bionomics.

## SEC filing metadata
- accession: 0001493152-26-008196
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315226008196/0001493152-26-008196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315226008196/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008196
- JSON: https://secwatch.observer/filing/0001493152-26-008196.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.